// App-Quantinova.ai

: International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A

Researchers

Presenter

  • Charles Pilette

Principal Investigators

  • Giorgio Walter Canonica

  • Rekha Chaudhuri

  • F. Eun-Hyung Lee

  • Jason Kihyuk Lee

  • Carlos Almonacid Sanchez

  • Rafael Alfonso-Cristancho

  • Rupert Jakes

  • Aoife Maxwell

  • Robert Price

  • Peter Howarth

Medical Centers

  • Real World Study Delivery, Value Evidence and Outcomes, Global Medical, GSK, Uxbridge, United Kingdom

  • Emory Vaccine Center, Emory University, Atlanta, GA, United States of America

  • Ramon y Cajal, Madrid, Spain

  • Value Evidence & Outcomes, GSK, Collegeville, PA, United States,

  • Cliniques universitaires Saint-Luc and Institute of Experimental and Clinical Research, UCLouvain, Bruxelles, Belgium

  • Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy Clinic, Humanitas Research Hospital, Milan, Italy

  • Biostatistics, GSK, Stevenage, United Kingdom

  • Global Medical, Global Specialty & Primary Care TA, GSK House, Brentford, United Kingdom

  • Evidence Based Medical Educator, Toronto Allergy and Asthma Clinic, Toronto, ON, Canada

  • Gartnavel General Hospital and University of Glasgow, Glasgow, United Kingdom

  • Epidemiology, LSHTM, London, United Kingdom

Locations

  • United States

  • United Kingdom

  • Canada

  • Italy

  • Belgium

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Observational

  • Single Arm

  • Multinational

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved